{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:11:21Z","timestamp":1790316681181,"version":"4.1.0"},"posted":{"date-parts":[[2025,4,3]]},"group-title":"In Review","reference-count":0,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,3,27]]},"abstract":"<title>Abstract<\/title>\n                <p>Alzheimer\u2019s disease (AD) is caused by the build-up of amyloid beta (A$\\beta$) proteins in the brain, leading to memory loss and cognitive decline. Despite the approval of monoclonal antibodies targeting A$\\beta$, optimizing treatment strategies while minimizing side effects remains a challenge. This study develops a mathematical framework to model A$\\beta$ aggregation dynamics, capturing the transition from monomers to higher-order aggregates, including protofibrils, toxic oligomers, and fibrils, using mass-action kinetics and coarse-grained modeling. Parameter estimation, sensitivity analysis, and data-driven calibration ensure model robustness. An optimal control framework is introduced to identify the optimal dose of the drug as a control function that reduces toxic oligomers and fibrils while minimizing adverse effects, such as amyloid-related imaging abnormalities (ARIA). The results indicate that Donanemab achieves the most significant reduction in fibrils. These findings provide a quantitative basis for optimizing AD treatments, providing valuable insight into the balance between therapeutic efficacy and safety.<\/p>","DOI":"10.21203\/rs.3.rs-6316455\/v1","type":"posted-content","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T11:46:33Z","timestamp":1743680793000},"source":"Crossref","is-referenced-by-count":2,"title":["Data-Driven Modeling of Amyloid-beta Targeted Antibodies for Alzheimer\u2019s Disease"],"prefix":"10.21203","author":[{"given":"Kobra","family":"Rabiei","sequence":"first","affiliation":[{"name":"Pennsylvania State University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Petrella","sequence":"additional","affiliation":[{"name":"Duke University Health System"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lenhart","sequence":"additional","affiliation":[{"name":"University of Tennessee at Knoxville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Liu","sequence":"additional","affiliation":[{"name":"Illinois Institute of Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Murali","family":"Doraiswamy","sequence":"additional","affiliation":[{"name":"Duke University Health System"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenrui","family":"Hao","sequence":"additional","affiliation":[{"name":"Pennsylvania State University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6316455\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6316455\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T16:08:50Z","timestamp":1764000530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6316455\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":0,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-6316455\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41540-025-00610-1","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,4,3]]},"subtype":"preprint"}}